SCHEMBL3067957

SCHEMBL3067957

O=C(O)Cn1ccc2c(Oc3ccc(NC(=O)c4ccc(Cl)c(Cl)c4)cn3)cccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 2/20 0.47
KCNQ2 O43526 2/20 0.47
KCNE1 P15382 2/20 0.47
KCNQ1 P51787 2/20 0.47
PTGDR2 Q9Y5Y4 4/20 0.45
PPARG P37231 4/20 0.44
PPARA Q07869 4/20 0.44
RHEB Q15382 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
PPARD Q03181 2/20 0.41
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3045763 0.89 KCNQ3 (0.44) KCNQ3KCNQ2KCNE1KCNQ1PTGDR2
SCHEMBL13742301 0.87 KDM4E (0.47) PTGDR2PPARGPPARARHEBKDM4E
SCHEMBL3058094 0.85 LOXL2 (0.44) KCNQ3KCNQ2KCNE1KCNQ1PTGDR2
SCHEMBL3069482 0.85 RAB9A (0.53) KCNQ3KCNQ2KCNE1KCNQ1PTGDR2
SCHEMBL3056414 0.79 MEN1 (0.48) KDM4EMEN1KMT2ANPC1MAPT
SCHEMBL10181012 0.78 LOXL2 (0.38) KCNQ3KCNQ2KCNE1KCNQ1PTGDR2
SCHEMBL13742591 0.77 MAPT (0.44) KDM4EMEN1KMT2ANPC1MAPT
SCHEMBL7235460 0.76 KCNQ3 (0.63) KCNQ3KCNQ2KCNE1KCNQ1KDM4E
SCHEMBL6180870 0.75 KCNQ3 (0.57) KCNQ3KCNQ2KCNE1KCNQ1KDM4E
SCHEMBL13742500 0.75 KDM4E (0.61) KCNQ3KCNQ2KCNE1KCNQ1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 KCNQ3 3852/4885KCNQ2 4218/4885KCNE1 3095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.